About Orphalan
At Orphalan we identify, develop and provide access to innovative treatments for patients with rare diseases.
We are an international orphan drug development and commercialization company headquartered in Paris.
Founded in 2011, we develop and deliver innovative therapies for people living with rare and debilitating diseases. Our trientine tetrahydrochloride product has been approved for the treatment of Wilson disease and is available in 30+ countries, branded as Cuprior® / Cuvrior®.
Our Approach
At Orphalan we listen to patients and put them at the core of all our work. Our primary focus is on rare, often fatal diseases where current therapeutic options do not exist, are suboptimal, or are associated with severe complications. Our efforts have resulted in the successful development and commercialization of therapies in global markets, including Europe and the United States. Further national submissions are in process to make our products available to patients worldwide.
By leveraging a global network of scientific and medical experts and partners, we develop comprehensive research and development programs, provide support to patients and their families, and raise awareness of orphan diseases.
Our Commitment
We develop and deliver innovative therapies for patients affected by rare diseases.
Over 7,000 rare diseases exist globally, many of which have limited or no therapeutic options. With an emphasis on supporting patients, our commitment is to work collaboratively with the rare disease and scientific communities to develop evidence-based treatments in areas of unmet need. Rare disease research matters because every patient matters, irrespective of the prevalence of their illness.
Our Values
Our work and commitment are underpinned by an unwavering dedication to patients. We are driven by a collective focus on our five values of being impactful, committed, collaborative, expert and dynamic.
Our Leadership Team
Our Board of Directors
Our Investors
We are proud to be backed by a high-quality group of leading investors, including Advent Life Sciences and Bpifrance, whose shared vision is to create a global business that delivers a meaningful and impactful difference to patients living with rare diseases.
Find out more
Our Research
We believe that patients across the world who are suffering with rare diseases should have access to innovative treatment that improves their care and positively impacts their lives and those of their loved ones.
